Advertisement

AAPS PharmSciTech

, Volume 19, Issue 7, pp 2787–2800 | Cite as

Particle Size Distribution Equivalency as Novel Predictors for Bioequivalence

  • Pratak Ngeacharernkul
  • Stephen D. Stamatis
  • Lee E. Kirsch
Research Article Theme: Team Science and Education for Pharmaceuticals: the NIPTE Model
  • 87 Downloads
Part of the following topical collections:
  1. Theme: Team Science and Education for Pharmaceuticals: the NIPTE Model

Abstract

The use of particle size distribution (PSD) similarity metrics and the development and incorporation of drug release predictions based on PSD properties into PBPK models for various drug administration routes may provide a holistic approach for evaluating the effect of PSD differences on in vitro drug release and bioavailability of disperse systems. The objectives of this study were to provide a rational approach for evaluating the utility of in vitro PSD comparators for predicting bioequivalence for subcutaneously administered test and reference drug emulsions. Two types of in vitro comparators for test and reference emulsion products were evaluated: PSD characterization comparators (overlap metrics, median, and span ratios) and release profile comparators (f2 and various fractional time ratios). A subcutaneous-input PBPK disposition model was developed to simulate blood concentration-time profiles of reference and test emulsion products and pharmacokinetic responses (e.g., AUC, Cmax, and Tmax) were used to determine bioequivalence. A pool of 10,440 pairs of test and reference products was simulated using Monte Carlo experiments. The PSD and release profile comparators were correlated to pass/fail bioequivalence metrics using logistical regression. Based on the use of single in vitro comparators, the f2 method was the best predictor of bioequivalence prediction. The use of combinations of f2 and PSD overlap comparators (e.g., OVL or PROB) improved bioequivalence prediction to about 90%. Simulation procedures used in this study demonstrated a process for developing reliable in vitro BE predictors.

KEY WORDS

bioequivalence particle size distribution modeling and simulation emulsion subcutaneous administration PBPK 

Notes

Funding Information

The authors gratefully acknowledge funding from the US‐FDA and the National Institute of Pharmaceutical Technology and Education through contract #5U01FD004275‐03; NIPTE‐2013‐002.

References

  1. 1.
    Crowder TM, Hickey AJ, Louey MD, Orr NA. Guide to pharmaceutical particulate science. London: Interpharm/CRC; 2003.CrossRefGoogle Scholar
  2. 2.
    U.S. National Archives and Records Administration. Title 21: Food and drugs. Chapter1-Food and Drug Administration. Code of Federal Regulations: part 320-bioavailability and bioequivalence requirements. 2017.Google Scholar
  3. 3.
    Food and Drug Administration. Draft guidance on cyclosporine: emulsion form/ophthalmic route. 2013.Google Scholar
  4. 4.
    Azzalini A, Capitanio A. The skew-normal and related families: Cambridge University Press; 2014. URL https://www.R-project.org/
  5. 5.
    Bikhazi AB, Higuchi WI. Interfacial barriers to the transport of sterols and other organic compounds at the aqueous polysorbate 80-hexadecane Interface. Biochim Biophys Acta Biomembr. 1971;233(3):676–87.CrossRefGoogle Scholar
  6. 6.
    Sweeney R, Langenberg JP, Maxwell DM. A physiologically based pharmacokinetic (PB/PK) model for multiple exposure routes of soman in multiple species. Arch Toxicol. 2006;80(11):719–31.CrossRefGoogle Scholar
  7. 7.
    Pamela N, Roy L, Celin D, Diana I, Emma P, Ian B, et al. Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site. J Oncol Pharm Pract. 2015;21(4):285–92.CrossRefGoogle Scholar
  8. 8.
    Nguyen HQ, Stamatis SD, Kirsch E. A novel method for assessing drug degradation product safety using physiologically-based pharmacokinetic models and stochastic risk assessment. J Pharm Sci. 2015;104(9):3101–19.CrossRefGoogle Scholar
  9. 9.
    Valentin J. Basic Anatomical and Physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2002;32(3–4):5–265.Google Scholar
  10. 10.
  11. 11.
    Gill KL, Houston JB, Galetin A. Characterization of in vitro Glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012;40(4):825–35.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hospira. Propofol Injectable Emulsion. https://www.pattersonvet.com/msds/078889390.
  13. 13.
    Avdeef A, Nielsen PE, Tsinman O. PAMPA-a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur J Pharm Sci. 2004;22(5):365–74.PubMedGoogle Scholar
  14. 14.
    Gill KL, Gertz M, Houston JB, Galetin A. Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data. Drug Metab Dispos. 2013;41(4):744–53.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rodgers T, Leahy D, Rowland M. Physiologically-based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259–76.CrossRefGoogle Scholar
  16. 16.
    Rodgers T, Rowland M. Physiologically-based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.CrossRefGoogle Scholar
  17. 17.
    Poulin P, Schoenlein K, Theil F-P. Prediction of adipose tissue:plasma partition coefficients for structurally unrelated drugs. J Pharm Sci. 2001;90(4):436–47.CrossRefGoogle Scholar
  18. 18.
    Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56.CrossRefGoogle Scholar
  19. 19.
    Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet. 2008;47(4):261–75.CrossRefGoogle Scholar
  20. 20.
    Doenicke AW, Roizen MF, Rau J, O'Connor M, Kugler J, Klotz U, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg. 1997;85(6):1399–403.CrossRefGoogle Scholar
  21. 21.
    Food and Drug Administration. Guidance for Industry: Bioequivalence Guidance. 2006.Google Scholar
  22. 22.
    Inman HF, Bradley EL. The overlapping coefficient as a measure of agreement between probability distributions and point estimation of the overlap of two normal densities. Commun Stat Theory Methods. 1989;18(10):3851–74.CrossRefGoogle Scholar
  23. 23.
    Gastwirth JL. Statistical measures of earnings differentials. Am Stat. 1975;29(1):32–5.Google Scholar
  24. 24.
    Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. 2003.Google Scholar
  25. 25.
    Food and Drug Administration. Guidance for Industry: immediate-release solid oral dosage forms: scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. 1995.Google Scholar
  26. 26.
    Food and Drug Administration. Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. 1997.Google Scholar
  27. 27.
    Food and Drug Administration. Guidance for Industry: SUPAC-MR: modified release solid oral dosage forms. Scale-up and post-approval changes: chemistry, manufacturing, and controls; in vitro dissolution testings and in vivo bioequivalence documentation. 1997.Google Scholar
  28. 28.
    Food and Drug Administration. Guidance for Industry: Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. 1997.Google Scholar
  29. 29.
    Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996:64–74.Google Scholar
  30. 30.
    O’Hara T, Dunne A, Butler J, Devane J. A review of methods used to compare dissolution profile data. Pharmaceutical Science & Technology Today. 1998;1(5):214–23.CrossRefGoogle Scholar
  31. 31.
    Duan J, Riviere K, Marroum P. In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match? Pharm Res. 2011;28(5):1144–56.CrossRefGoogle Scholar
  32. 32.
    Xie F, Ji S, Cheng Z. In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example. Eur J Pharm Sci. 2015;66(0):163–72.CrossRefGoogle Scholar
  33. 33.
    Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–33.CrossRefGoogle Scholar
  34. 34.
    Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–96.CrossRefGoogle Scholar
  35. 35.
    LeBlond D, Altan S, Novick S, Peterson J, Shen Y, Yang H. In vitro dissolution curve comparisons: a critique of current practice. Dissolution Technologies. 2016;23:14–23.CrossRefGoogle Scholar
  36. 36.
    Food and Drug Administration. Guidance for Industry: dissolution testing and specification criteria for immediate-release solid oral dosage forms containing biopharmaceutics classification system class 1 and 3 drugs. 2015.Google Scholar
  37. 37.
    Food and Drug Administration. Guidance for industry: statistical approaches to establishing bioequivalence. 2001.Google Scholar
  38. 38.
    Artursson P. Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells. J Pharm Sci. 1990;79(6):476–82.CrossRefGoogle Scholar
  39. 39.
    Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175(3):880–5.CrossRefGoogle Scholar
  40. 40.
    Haeberlin B, Rubas W, Nolen IIIHW, Friend DR. In vitro evaluation of dexamethasone-β-D-glucuronide for colon-specific drug delivery. Pharm Res. 1993;10(11):1553–62.CrossRefGoogle Scholar
  41. 41.
    Rubas W, Jezyk N, Grass GM. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res. 1993;10(1):113–8.CrossRefGoogle Scholar
  42. 42.
    Hovgaard L, Brøndsted H, Buur A, Bundgaard H. Drug delivery studies in Caco-2 monolayers. Synthesis, hydrolysis, and transport of O-cyclopropane carboxylic acid ester prodrugs of various β-blocking agents. Pharm Res. 1995;12(3):387–92.CrossRefGoogle Scholar
  43. 43.
    Augustijns P, D'Hulst A, Van Daele J, Kinget R. Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci. 1996;85(6):577–9.CrossRefGoogle Scholar
  44. 44.
    Collett A, Sims E, Walker D, He Y-L, Ayrton J, Rowland M, et al. Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res. 1996;13(2):216–21.CrossRefGoogle Scholar
  45. 45.
    Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res. 1997;14(6):763–6.CrossRefGoogle Scholar
  46. 46.
    Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res. 1998;15(9):1490–4.CrossRefGoogle Scholar
  47. 47.
    Zhu C, Jiang L, Chen T-M, Hwang K-K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem. 2002;37(5):399–407.CrossRefGoogle Scholar
  48. 48.
    Saha P, Kou JH. Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur J Pharm Biopharm. 2002;54(3):319–24.CrossRefGoogle Scholar
  49. 49.
    Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight. Eur J Pharm Sci. 1998;6(4):313–9.CrossRefGoogle Scholar
  50. 50.
    Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006;23(6):1144–56.CrossRefGoogle Scholar
  51. 51.
    Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Yu LX. Biopharmaceutics classification of selected β-blockers: solubility and permeability class membership. Mol Pharm. 2007;4(4):608–14.CrossRefGoogle Scholar
  52. 52.
    Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci. 2013;49(4):679–98.CrossRefGoogle Scholar
  53. 53.
    Schipper NGM, Osterberg T, Wrange U, Westberg C, Sokolowski A, Rai R, et al. In vitro intestinal permeability of factor Xa inhibitors: influence of chemical structure on passive transport and susceptibility to efflux. Pharm Res. 2001;18(12):1735–41.CrossRefGoogle Scholar
  54. 54.
    National Center for Biotechnology Information. PubChem compound database. Available from: https://pubchem.ncbi.nlm.nih.gov/.
  55. 55.
    Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147–58.CrossRefGoogle Scholar
  56. 56.
    Schmitt JM, Zhou GX, Walker EC. Multilayer model of photon diffusion in skin. J Opt Soc Am A. 1990;7(11):2141–53.CrossRefGoogle Scholar
  57. 57.
    Shalizi CR. Logistic Regression. In: Advanced data analysis from an elementary point of view. Carnegie Mellon University; 2017. p. 251–280.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Pratak Ngeacharernkul
    • 1
  • Stephen D. Stamatis
    • 1
    • 2
  • Lee E. Kirsch
    • 1
  1. 1.Division of PharmaceuticsThe University of IowaIowa CityUSA
  2. 2.Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA

Personalised recommendations